<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215265</url>
  </required_header>
  <id_info>
    <org_study_id>2014/VCC/0014</org_study_id>
    <nct_id>NCT02215265</nct_id>
  </id_info>
  <brief_title>Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)</brief_title>
  <acronym>PATHOS</acronym>
  <official_title>A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisette Nixon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Alexandra Hospital, Brisbane, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Velindre NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the PATHOS study are:&#xD;
&#xD;
      To assess whether swallowing function can be improved following transoral resection of&#xD;
      HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to&#xD;
      personalise treatment, based on disease biology (HPV status and pathology findings), to&#xD;
      optimise patient outcomes.&#xD;
&#xD;
      To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols&#xD;
      in terms of overall survival in the reduced intensity treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PATHOS is a multicentre, open-label, parallel-group Phase II/III randomised controlled trial&#xD;
      (RCT). The phase II target of 242 patients was reached in December 2018 and there was a&#xD;
      seamless transition into Phase III. The protocol was amended in September 2018 to incorporate&#xD;
      the changes associated with the phase III transition. The amendment included changes to the&#xD;
      outcome measures and sample size calculations.&#xD;
&#xD;
      Approximately 1100 patients will be recruited to the phase III study. Patients eligible for&#xD;
      the study must have biopsy proven oropharyngeal squamous cell carcinoma (OPSCC) clinically&#xD;
      staged T1T3 N0N2b. Their primary tumour, as judged by the local MDT, must be considered&#xD;
      resectable via a transoral approach. Having secured informed consent, patients with centrally&#xD;
      or locally determined HPV positive tumours will undergo baseline assessment of swallowing&#xD;
      function (includesÍ¾ MDADI score, videofluoroscopy, PSSH&amp; N, 100 mL water swallow test) and&#xD;
      complete QOL questions (EORTC QLQC30 and EORTC QLQH&amp;N35) prior to surgery.&#xD;
&#xD;
      Transoral Laser Microsurgery, Transoral Robotic Surgery &amp; Endoscopically assisted Transoral&#xD;
      Surgery are all accepted transoral techniques for the study. A lateral oropharyngectomy&#xD;
      performed with monopolar cautery (The Huet Procedure) can also be used.&#xD;
&#xD;
      Following surgery and histopathological assessment of the primary tumour and neck dissection&#xD;
      surgical specimens, patients will be allocated into study groups based on the presence or&#xD;
      absence of pathological risk factors for recurrence as follows:&#xD;
&#xD;
      Group A: Patients with tumours which exhibit no adverse histological features. Patients in&#xD;
      this group will not receive any adjuvant treatment as per standard of care.&#xD;
&#xD;
      Group B: Patients with T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th&#xD;
      edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in&#xD;
      multiple ipsilateral nodes &lt;61 mm diameter) disease, tumours with evidence of perineural&#xD;
      and/or vascular invasion, and/or a histologically normal tissue margin around the primary&#xD;
      tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour (section 7.1).&#xD;
      Patients in this group will be randomised to PORT 60Gy in 30# over 6 weeks (Control Arm B1)&#xD;
      or PORT 50Gy in 25# over 5 weeks (Test Arm B2).&#xD;
&#xD;
      Group C: Patients with tumours of any T or any N stage, which exhibit the following high-risk&#xD;
      pathological features will be included: A histologically normal tissue margin around the&#xD;
      primary tumour of &lt;1mm and, in the case of TLM, marginal biopsies free of tumour and /or&#xD;
      extracapsular spread (ECS) of nodal disease. Patients in this group will be randomised to&#xD;
      POCRT 60Gy in 30# over 6 weeks with concurrent Cisplatin (Control Arm C1) or PORT 60Gy in 30#&#xD;
      over 6 weeks without chemotherapy (Test Arm C2).&#xD;
&#xD;
      Patients in groups B and C will be stratified before randomisation by T stage, N stage,&#xD;
      smoking history and treating centre.&#xD;
&#xD;
      The same assessments as at baseline will be completed post-operatively prior to treatment and&#xD;
      then at four weeks and 6, 12 and 24 months post-treatment. The exception is videofluoroscopy&#xD;
      which will be repeated at post-surgery and 12 months only.&#xD;
&#xD;
      Acute and late toxicity will be recorded weekly during treatment and again at 4 weeks and 6,&#xD;
      12 and 24 months post-treatment.&#xD;
&#xD;
      The time point of assessments should be recorded on the CRF. Complications relating to&#xD;
      surgery will be recorded in the CRF. In particular, any complications which necessitate a&#xD;
      delay to the start of adjuvant treatment.&#xD;
&#xD;
      Data registry: The top copy of each completed CRF should be returned to the CTR for data&#xD;
      entry within four weeks of the visit. The remaining copy is to be retained at the local site.&#xD;
      In accordance with the principles of GCP, the PI is responsible for ensuring accuracy,&#xD;
      completeness, legibility and timeliness of the data reported to the CTR in the CRFs. CRF&#xD;
      pages and data received by the CTR from participating trial sites will be checked for&#xD;
      missing, illegible or unusual values (range checks) and consistency over time.&#xD;
&#xD;
      If missing or questionable data are identified, a data query will be raised on a data&#xD;
      clarification form. The data clarification form will be sent to the relevant participating&#xD;
      site. The site shall be requested to answer the data query or correct data on the data&#xD;
      clarification form. The CRF pages should not be altered.&#xD;
&#xD;
      All answered data queries and corrections should be signed off and dated by a delegated&#xD;
      member of staff at the relevant participating site. The completed data clarification form&#xD;
      should be returned to the CTR and a copy retained at the site along with the participants'&#xD;
      CRFs.&#xD;
&#xD;
      The CTR will send reminders for any overdue data. It is the site's responsibility to submit&#xD;
      complete and accurate data in a timely manner.&#xD;
&#xD;
      An electronic database has been developed for the study and will be implemented at all the&#xD;
      international sites. Local UK sites will also transition to the electronic database for&#xD;
      participants enrolled after implementation.&#xD;
&#xD;
      Quality assurance: The clinical trial risk assessment has been used to determine the&#xD;
      intensity and focus of central and on-site monitoring activity in the PATHOS trial.&#xD;
      Monitoring levels will be employed and are fully documented in the trial monitoring plan.&#xD;
      Investigators should agree to allow trial-related monitoring, including audits and regulatory&#xD;
      inspections, by providing direct access to source data/documents as required. Patient consent&#xD;
      for this will be obtained.&#xD;
&#xD;
      Registration: To register or randomise a patient the relevant registration or randomisation&#xD;
      case report form (CRF) should be completed and the CTR contacted. For International sites and&#xD;
      UK sites that have transitioned to electronic database, the registration process can be done&#xD;
      electronically without the need to contact CTR. Randomisation will take place centrally after&#xD;
      confirmation of eligibility, by a telephone call to the CTR. Participants will be randomised&#xD;
      using minimisation with a random element. This will ensure balanced treatment allocation by&#xD;
      clinically important stratification factors. Randomisation will have an allocation ratio of&#xD;
      1:1.&#xD;
&#xD;
      Statistical analyses:&#xD;
&#xD;
      Primary outcome measure&#xD;
&#xD;
      MDADI/Overall survival co-primary endpoint&#xD;
&#xD;
      Secondary outcome measures&#xD;
&#xD;
        -  Swallowing panel including qualitative and quantitative swallowing assessments (100ml&#xD;
           Water Swallow Test, Videofluoroscopy, Performance Status Scale-Head &amp; Neck)&#xD;
&#xD;
        -  QOL (using validated EORTC QLQ C30 and HN35 questionnaires, Appendix 6)&#xD;
&#xD;
        -  Acute and late toxicity using CTACE version 4.03&#xD;
&#xD;
        -  Disease-Free Survival*&#xD;
&#xD;
        -  Locoregional control*&#xD;
&#xD;
        -  Distant Metastases* *Determined by clinical follow-up as per standard guidelines (no&#xD;
           trial-specific imaging required)&#xD;
&#xD;
      The co-primary endpoint of the Phase III will be MDADI and overall survival (time to event).&#xD;
&#xD;
      We will use linear regression to estimate the treatment arm effect on MDADI at 12 months and&#xD;
      will include the randomisation stratification variables and baseline MDADI in the model. Both&#xD;
      OS and MDADI endpoints will be used to define study success so no adjustment for multiplicity&#xD;
      is planned. A detailed statistical analysis plan will be developed before the analyses are&#xD;
      conducted.&#xD;
&#xD;
      The data will be reviewed (approximately six-monthly) by an Independent Data Monitoring&#xD;
      Committee (IDMC), consisting of at least two Clinicians (not entering patients into the&#xD;
      trial) and an independent Statistician. The IDMC will be asked to recommend whether the&#xD;
      accumulated data from the trial, together with results from other relevant trials, justifies&#xD;
      continuing recruitment of further patients. A decision to discontinue recruitment, in all&#xD;
      patients or selected subgroups, will be made only if the result is likely to convince a broad&#xD;
      range of Clinicians including PIs in the trial and the general clinical community. If a&#xD;
      decision is made to continue, the IDMC will advise on the frequency of future reviews of the&#xD;
      data based on accrual and event rates.&#xD;
&#xD;
      Sub-group statistical analyses:&#xD;
&#xD;
      For swallowing endpoints, subgroup analysis by T stage and tumour subsite (tonsil, soft&#xD;
      palate, tongue base) and surgery technique will be carried out, as the most likely relevant&#xD;
      clinical co-variables affecting swallowing function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MDADI/Overall survival co-primary endpoint</measure>
    <time_frame>At 12 months following treatment measured using the MD Anderson Dysphagia Inventory (MDADI) score.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swallowing panel including qualitative and quantitative swallowing assessments</measure>
    <time_frame>Baseline; 4 weeks (+/- 2 weeks) post-surgery, prior to start of any adjuvant treatment; 4 weeks (+/- 2 weeks) post treatment; 6 months (+/- 4 weeks) post treatment; 12 months (+/- 4 weeks) post treatment; 24 months (+/- 8 weeks) post treatment.</time_frame>
    <description>Water swallow test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL (using validated EORTC QLQ C30 and HN35 questionnaires)</measure>
    <time_frame>Baseline; 4 weeks (+/- 2 weeks) post-surgery, prior to start of any adjuvant treatment; 4 weeks (+/- 2 weeks) post treatment; 6 months (+/- 4 weeks) post treatment; 12 months (+/- 4 weeks) post treatment; 24 months (+/- 8 weeks) post treatment.</time_frame>
    <description>Quality of Life (QOL) questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity using CTACE version 4.03</measure>
    <time_frame>Weekly during RT and at end of treatment; 4 weeks (+/- 2 weeks) post-surgery, prior to start of any adjuvant treatment; 4 weeks (+/- 2 weeks), 6 months (+/- 4 weeks), 12 months (+/- 4 weeks), and 24 months (+/- 8 weeks) post treatment.</time_frame>
    <description>Toxicity assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>6 months intervals</time_frame>
    <description>Determined by clinical follow up as per standard guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>6 months intervals</time_frame>
    <description>Determined by clinical follow up as per standard guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastases</measure>
    <time_frame>6 months intervals</time_frame>
    <description>Determined by clinical follow up as per standard guidelines</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>A: No adjuvant treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1: Postoperative radiotherapy 60 Gray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.&#xD;
Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes &lt;61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2: Postoperative radiotherapy 50 Gray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.&#xD;
Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes &lt;61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1: Postoperative radiotherapy 60 Gray with Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.&#xD;
Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of &lt;1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2: Postoperative radiotherapy 60 Gray without chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).&#xD;
Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of &lt;1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>C1: Postoperative radiotherapy 60 Gray with Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Postoperative radiotherapy</intervention_name>
    <description>Postoperative radiotherapy (PORT)</description>
    <arm_group_label>B1: Postoperative radiotherapy 60 Gray</arm_group_label>
    <arm_group_label>B2: Postoperative radiotherapy 50 Gray</arm_group_label>
    <arm_group_label>C1: Postoperative radiotherapy 60 Gray with Cisplatin</arm_group_label>
    <arm_group_label>C2: Postoperative radiotherapy 60 Gray without chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed or suspected squamous cell carcinoma of the oropharynx.&#xD;
&#xD;
          -  UICC/AJCC TNM 7th edition stage T1-T3, N0-N2b (or UICC TNM 8th edition stage T1-T3,&#xD;
             N0-N1) disease. [Staging should be based on cross sectional imaging investigations&#xD;
             carried out within 10 weeks of study entry].&#xD;
&#xD;
          -  Multidisciplinary team (MDT) decision to treat with primary transoral resection and&#xD;
             neck dissection.&#xD;
&#xD;
          -  Patients considered fit for surgery and adjuvant radiotherapy&#xD;
&#xD;
          -  Aged 18 or over.&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known HPV negative squamous cell carcinomas of the head and neck: A negative result&#xD;
             for p16 Immunohistochemistry automatically excludes a patient from the trial. If&#xD;
             initial p16 testing is positive but High Risk HPV (HR HPV) In-Situ Hybridization&#xD;
             (ISH)/Polymerase Chain Reaction (PCR) does not demonstrate the presence of HR HPV DNA,&#xD;
             the patient will also be excluded. Patients who are p16+ may complete swallowing&#xD;
             assessments, excluding videofluoroscopy, and surgery whilst HR HPV DNA status is being&#xD;
             determined (with recourse to central concordance testing, if appropriate, for UK&#xD;
             centres). HPV positivity, as determined by p16 and the demonstration of HR HPV DNA is&#xD;
             essential before patients undergo videofluoroscopy or randomisation.&#xD;
&#xD;
          -  T4 and/or T1-T3 tumours where transoral surgery is considered not feasible.&#xD;
&#xD;
          -  UICC/AJCC TNM 7th edition N2c-N3 nodal disease (or UICC/AJCC TNM 8th edition N2-N3&#xD;
             nodal disease).&#xD;
&#xD;
          -  Patients for whom transoral surgery and neck dissection is not considered the primary&#xD;
             treatment modality.&#xD;
&#xD;
          -  Current smokers with N2b disease (including smokers up to 6 months before diagnosis),&#xD;
             even if HPV-positive. Vaping is permitted and should be considered as non-smoking&#xD;
             status.&#xD;
&#xD;
          -  Any pre-existing medical condition likely to impair swallowing function and/ or a&#xD;
             history of pre-existing swallowing dysfunction prior to index oropharyngeal cancer.&#xD;
&#xD;
          -  Patients with distant metastatic disease as determined by routine pre-operative&#xD;
             staging radiological investigations e.g., CT thorax and upper abdomen or PET-CT.&#xD;
&#xD;
          -  Patients with a history of malignancy in the last 5 years, except basal cell carcinoma&#xD;
             of the skin or carcinoma in-situ of the cervix.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding and fertile women who will not be using&#xD;
             contraception during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mererid Evans, MBBch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Velindre NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terrence Jones, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aintree University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Haughey</last_name>
      <phone>407-303-0409</phone>
      <email>bruce.haughey.md@flhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Guyler</last_name>
      <phone>407-543-4000</phone>
      <phone_ext>1203655</phone_ext>
      <email>Sara.Guyler@AdventHealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metro South Health</name>
      <address>
        <city>Brisbane</city>
        <zip>QLD 4113</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben Panizza, Prof</last_name>
      <email>ben@panizza.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Organisation for Research and Treatment of Cancer</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Simon</last_name>
      <email>Christian.Simon@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unicancer</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haitham Mirghani (National Coordinator)</last_name>
      <email>haitham.mirghani@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Blanchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poole Hospital NHS Foundation Trust</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma King, Dr</last_name>
      <email>emmabarker@doctors.org.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospitals Bath NHS Foundation Trust</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma De Winton, Dr</last_name>
      <email>emma.dewinton@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hartley, Dr</last_name>
      <email>andrew.hartley@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Blackburn Hospital</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 3HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naseem Ghazali, Miss</last_name>
      <email>naseem.ghazali@elht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Beasley, Dr</last_name>
      <email>Matthew.Beasley@UHBristol.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irune Ekpemi, Miss</last_name>
      <email>ekpemi.irune@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HPV Research Group Section of Pathology Cardiff University ,School of Medicine</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ned Powell, Dr</last_name>
      <email>PowellNG@cardiff.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Local Health Board</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Owens, Mr</last_name>
      <email>david.owens2@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Trials Research</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4YS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Hurt</last_name>
      <phone>02920687471</phone>
      <email>HurtCN@cardiff.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust</name>
      <address>
        <city>Cardiff</city>
        <zip>CF142TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mererid Evans, Professor</last_name>
      <email>Mererid.Evans@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorcan O'Toole, Dr</last_name>
      <email>lorcan.otoole@hey.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derby Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Mortimore, Mr</last_name>
      <email>sean.mortimore@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iain Nixon, Mr</last_name>
      <email>iain.nixon@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Derbyshire, Mr</last_name>
      <email>stephen.derbyshire2@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Cardale, Dr</last_name>
      <email>kate.cardale@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L3 9TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Jones, Professor</last_name>
      <email>T.M.Jones@liverpool.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L69 3GB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne Patterson, Prof</last_name>
      <email>Joanne.Patterson@liverpool.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cwm Taf University Health Board</name>
      <address>
        <city>Llantrisant</city>
        <zip>CF72 8XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Webster, Dr</last_name>
      <email>Richard.Webster@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hughes, Mr</last_name>
      <email>jonathan.hughes1@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas's NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asit Arora, Mr</last_name>
      <email>Asit.Arora@gstt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Georges University Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enyinnaya Ofo</last_name>
      <phone>0208 725 2052</phone>
      <email>enyinnaya.ofo@stgeorges.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaid Awad, Mr</last_name>
      <email>zawad@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarrod Homer, Professor</last_name>
      <email>jarrod.j.homer@manchester.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Thomson, Dr</last_name>
      <email>david.thomson@christie.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Pennine Acute Hospital Trust</name>
      <address>
        <city>Manchester</city>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panos Kyzas, Mr</last_name>
      <email>Panayiotis.Kyzas@pat.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Lester, Mr</last_name>
      <email>shanelester@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conrad Robinson, Dr</last_name>
      <email>max.robinson@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James O'Hara, Mr</last_name>
      <email>James.Ohara@nuth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aneurin Bevan University Health Board</name>
      <address>
        <city>Newport</city>
        <zip>NP18 3XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Passant, Mr</last_name>
      <email>Carl.Passant@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Winter, Mr</last_name>
      <email>stuart.winter@ouh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Plymouth</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Williams, Mr</last_name>
      <email>richard.williams8@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costa Repanos, Mr</last_name>
      <email>costa.repanos@porthosp.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Dallas, Dr</last_name>
      <email>Nicola.Dallas@royalberkshire.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satish Harinarayanan, Dr</last_name>
      <email>sathish.harinarayanan@uhs.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Cocks, Dr</last_name>
      <email>helen.cocks@chsft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abertawe Bro Morgannwg University Health Board</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conor Marnane, Mr</last_name>
      <email>conor.marnane@wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Velindre NHS Trust</investigator_affiliation>
    <investigator_full_name>Lisette Nixon</investigator_full_name>
    <investigator_title>Trial Manager</investigator_title>
  </responsible_party>
  <keyword>Human papillomavirus HPV positive oropharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

